CY1119940T1 - Παραγοντας για χρηση στην περιπτωση δυσανεξιας στη φρουκτοζη - Google Patents

Παραγοντας για χρηση στην περιπτωση δυσανεξιας στη φρουκτοζη

Info

Publication number
CY1119940T1
CY1119940T1 CY20181100218T CY181100218T CY1119940T1 CY 1119940 T1 CY1119940 T1 CY 1119940T1 CY 20181100218 T CY20181100218 T CY 20181100218T CY 181100218 T CY181100218 T CY 181100218T CY 1119940 T1 CY1119940 T1 CY 1119940T1
Authority
CY
Cyprus
Prior art keywords
fructose
case
agent
fruitsosis
tolerance
Prior art date
Application number
CY20181100218T
Other languages
English (en)
Inventor
Daniel Henry Wyrobnik
Isaak Harry Wyrobnik
Elliad Ronen Silcoff
Original Assignee
Pro Natura Gesellschaft für gesunde Ernährung mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006012244A external-priority patent/DE102006012244A1/de
Priority claimed from DE102006013624A external-priority patent/DE102006013624B4/de
Application filed by Pro Natura Gesellschaft für gesunde Ernährung mbH filed Critical Pro Natura Gesellschaft für gesunde Ernährung mbH
Publication of CY1119940T1 publication Critical patent/CY1119940T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01124—Fructose 5-dehydrogenase (NADP+) (1.1.1.124)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01005—Xylose isomerase (5.3.1.5)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Abstract

Η παρούσα εφεύρεση αναφέρεται σε έναν παράγοντα προς χρήση στην περίπτωση της δυσανεξίας στη φρουκτόζη και σε οποιαδήποτε μορφή εξασθένισης και προσβολής της υγείας και της ευεξίας που προκαλείται από τη χορήγηση τροφών που περιέχουν φρουκτόζη ή τρόφιμα που περιλαμβάνουν φρουκτόζη ή από την απελευθέρωση της φρουκτόζης στον γαστρεντερικό σωλήνα ανθρώπων ή ζώων α, όπως π.χ. σακχαρόζη. Ο παράγοντας σύμφωνα με την εφεύρεση περιλαμβάνει αφυδρογονάση 5-D-φρουκτόζης, προαιρετικά σε συνδυασμό με ινβερτάση και/ή μαλτάση και/ή ισομεράση γλυκόζης, τα οποία ένζυμα ή συνδυασμός ενζύμων χρησιμοποιούνται στο ιατρικό πεδίο για πρώτη φορά. Κατά προτίμηση ο παράγοντας είναι στη μορφή μιας φαρμακευτικής σύνθεσης, η οποία είναι χρήσιμη για τη θεραπεία της δυσανεξίας στη φρουκτόζη.
CY20181100218T 2005-11-16 2018-02-22 Παραγοντας για χρηση στην περιπτωση δυσανεξιας στη φρουκτοζη CY1119940T1 (el)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
DE102005055081 2005-11-16
DE102005056169 2005-11-23
DE102005060768 2005-12-16
DE102005060769 2005-12-16
DE102006000873 2006-01-04
DE102006000881 2006-01-04
DE102006001015 2006-01-05
US75742406P 2006-01-10 2006-01-10
US75741406P 2006-01-10 2006-01-10
DE102006012244A DE102006012244A1 (de) 2005-11-16 2006-03-15 Mittel zur Anwendung bei Fructoseintoleranz
DE102006013624A DE102006013624B4 (de) 2005-11-23 2006-03-22 Mittel zur Anwendung bei Fructoseintoleranz
DE102006014423 2006-03-27
US83105006P 2006-07-17 2006-07-17
US83117406P 2006-07-17 2006-07-17
PCT/IB2006/003223 WO2007057749A2 (en) 2005-11-16 2006-11-15 Agent for use in the case of fructose intolerance

Publications (1)

Publication Number Publication Date
CY1119940T1 true CY1119940T1 (el) 2018-12-12

Family

ID=38049014

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100218T CY1119940T1 (el) 2005-11-16 2018-02-22 Παραγοντας για χρηση στην περιπτωση δυσανεξιας στη φρουκτοζη

Country Status (13)

Country Link
US (3) US20090081300A1 (el)
EP (2) EP1951290B1 (el)
JP (1) JP2009519897A (el)
KR (1) KR20080080122A (el)
AU (1) AU2006314188B2 (el)
CA (1) CA2669431C (el)
CY (1) CY1119940T1 (el)
HR (1) HRP20180327T1 (el)
IL (1) IL191363B (el)
PL (1) PL1951290T3 (el)
SI (1) SI1951290T1 (el)
WO (1) WO2007057749A2 (el)
ZA (1) ZA200805143B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211517B2 (en) * 2005-11-23 2016-06-30 Pro Natura Gesellschaft Fur Gesunde Ernahrung Mbh Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
US20090060956A1 (en) * 2005-11-23 2009-03-05 Daniel Henry Wyrobnik Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
DE102007008664B4 (de) * 2007-02-20 2021-07-29 Vitacare Gmbh & Co. Kg Mittel zur Anwendung bei Fructoseintoleranz
EP2161034A1 (de) 2008-09-04 2010-03-10 Sciotec Diagnostic Technologies GmbH Behandlung von Fruktose-Malabsorption
DK2340035T3 (da) 2008-09-04 2014-10-20 Sciotec Diagnostic Technologies Gmbh Behandling af fruktosemalabsorption
WO2010107414A1 (en) * 2009-03-19 2010-09-23 Amano Enzyme Inc. Enzyme compositions and use thereof
EP3415631A1 (en) 2017-06-13 2018-12-19 RWTH Aachen Methods of producing 5-ketofructose
EP3969606A4 (en) * 2019-05-13 2023-01-11 Sami-Sabinsa Group Limited LACTIC ACID PRODUCING FRUCTOPHILIC BACTERIA
CN112536005B (zh) * 2020-11-05 2022-05-03 华南理工大学 一种淀粉包埋香气物质微胶囊及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107291A (en) * 1969-06-05 1978-08-15 Sankyo Company Limited Compositions for cleaning teeth and oral cavity
US4396602A (en) * 1981-09-22 1983-08-02 Asahi Kasei Kogyo Kabushiki Kaisha Blood glucose level lowering agents
DK8502857A (el) * 1984-06-25 1985-12-26
JPS6236191A (ja) * 1985-08-09 1987-02-17 House Food Ind Co Ltd 固定化酵素の製造方法
SE8505783D0 (sv) 1985-12-06 1985-12-06 Rolf Bergkvist Forfarande for framstellning av livsmedelsprodukter och dessas anvendning
JPH0640824B2 (ja) * 1987-03-19 1994-06-01 東洋紡績株式会社 安定なフラクト−スデヒドロゲナ−ゼ組成物
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
FI905402A (fi) 1990-11-01 1992-05-02 Alko Ab Oy Oligosackaridblandning och foerfarande foer dess efterbehandling.
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
WO1998057653A1 (en) 1997-06-17 1998-12-23 Novo Nordisk A/S An oral care composition comprising a bacillus pullulanase and a dextranase
EP1002114A1 (en) * 1997-06-17 2000-05-24 Monsanto Company Expression of fructose 1,6 bisphosphate aldolase in transgenic plants
CA2331741C (en) * 1998-05-13 2011-12-06 Novo Nordisk Biotech, Inc. Methods for using dehydrogenases in baking
WO1999062343A1 (en) * 1998-05-29 1999-12-09 Novo Nordisk A/S Methods for using xyloglucan endotransglycosylase in baking
US6042823A (en) 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
JP2000125883A (ja) * 1998-10-21 2000-05-09 Internatl Reagents Corp フルクトキナーゼ及びその遺伝子
WO2000027215A1 (en) 1998-11-05 2000-05-18 Novozymes A/S Methods for using a glucose isomerase in baking
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
EP1203822A1 (en) * 2000-11-02 2002-05-08 Societe Des Produits Nestle S.A. Extracellular polysaccharide from Gluconacetobacter spp
US6754884B1 (en) 2001-07-02 2004-06-22 Bea Systems, Inc. Programming language extensions for processing XML objects and related applications
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
US20030113310A1 (en) * 2001-12-17 2003-06-19 Van Laere Katrien Maria Jozefa Method for the treatment of obesity, overweight and fluctuations in blood insuline and/or glucose levels
ES2293012T3 (es) * 2002-10-11 2008-03-16 Novozymes A/S Metodo para preparar un producto tratado con calor.
JP2004261174A (ja) * 2003-02-13 2004-09-24 Fujicco Co Ltd 豆乳発酵物およびそれを用いた飲食品
US20060269826A1 (en) 2003-03-03 2006-11-30 Eugenii Katz Novel electrode with switchable and tunable power output and fuel cell using such electrode
US20080044504A1 (en) * 2004-07-05 2008-02-21 Marukin Bio, Inc. Pomegranate Juice, Pomegranate Juice Powder and Process for Producing the Powder
US20090060956A1 (en) * 2005-11-23 2009-03-05 Daniel Henry Wyrobnik Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)

Also Published As

Publication number Publication date
AU2006314188B2 (en) 2014-01-16
AU2006314188A1 (en) 2007-05-24
US10568942B2 (en) 2020-02-25
ZA200805143B (en) 2012-02-29
US9446101B2 (en) 2016-09-20
US20180344818A1 (en) 2018-12-06
CA2669431A1 (en) 2007-05-24
WO2007057749A3 (en) 2008-10-16
HRP20180327T1 (hr) 2018-04-06
EP1951290A2 (en) 2008-08-06
PL1951290T3 (pl) 2018-05-30
SI1951290T1 (en) 2018-04-30
EP1951290B1 (en) 2017-12-27
WO2007057749A2 (en) 2007-05-24
EP1951290A4 (en) 2009-03-11
US20130224171A1 (en) 2013-08-29
CA2669431C (en) 2019-04-23
IL191363B (en) 2018-05-31
US20090081300A1 (en) 2009-03-26
KR20080080122A (ko) 2008-09-02
EP3318271A1 (en) 2018-05-09
JP2009519897A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
CY1119940T1 (el) Παραγοντας για χρηση στην περιπτωση δυσανεξιας στη φρουκτοζη
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
CY1117312T1 (el) Θεραπευτικη αγωγη συνουκλεϊνοπαθειων
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
GT200500205A (es) Nuevos anticuerpos anti-igf-ir y sus usos
HK1118011A1 (zh) 透明質酸的抗腫瘤生物結合物或以化學接合方法間接地取得的衍生物，以及其製藥用途
CY1120085T1 (el) Παραγοντας προς χρηση στην περιπτωση δυσανεξιας στην φρουκτοζη
BR112012029395A2 (pt) lactamas piperdinil-substituídas como moduladores de gpr119
CY1119850T1 (el) Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
DK1719503T3 (da) Anvendelse af stivelse med fraspaltede sidekæder i ekstrudering/sfæronisering af farmaceutiske pellets
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
CY1114125T1 (el) Αδιπονεκτινη στην αγωγη εναντι πνευμονοπαθειας
EA200900259A1 (ru) Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
JP2009292763A5 (el)